Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant

Major Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment into the study: * Capable of understanding the protocol requirements and risks and providing written informed consent. * Histologically or cytologically confirmed diagnosis of multiple myeloma. * Mannose-binding lectin level \<300 ng/mL. * Age ≥18 years old. * Score of 0 to 2 on the Zubrod performance status scale. * Patient is scheduled to receive melphalan-based high-dose chemotherapy and autologous HSCT for the treatment of multiple myeloma. Exclusion Criteria: * Concurrent serious medical illness that could potentially interfere with protocol compliance. * Concurrent or previous malignancy associated with a poor prognosis. * Known chronic infectious disease, such as acquired immunodeficiency syndrome (AIDS) or hepatitis (for hepatitis and human immunodeficiency virus \[HIV\] will not be performed). * Positive screening pregnancy test or is breast-feeding. * Female or male patient of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during the course of this protocol. * Known or clinically suspected active brain metastases. * Current participation in another clinical study with an investigational agent and/or use of an investigational drug.